Please login to the form below

Not currently logged in
Email:
Password:

HTA bodies

This page shows the latest HTA bodies news and features for those working in and with pharma, biotech and healthcare.

Nature's way

Nature's way

Not to belittle recent advances or the brilliance of my colleagues in that area, but health technology assessment (HTA) is both harder and more difficult than drug or device safety assessment ... But our health economic capabilities are not there yet. If

Latest news

More from news
Approximately 0 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Market shaping demands behaviour change Market shaping demands behaviour change

    In fact, a 2019 study conducted by the German HTA organisation IQWiG concluded that they deem two-thirds of new innovations reaching the market today offer limited or no additional value ... It is now used extensively in policy and healthcare, with

  • Market shaping for better healthcare decisions Market shaping for better healthcare decisions

    In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    The access landscape is further complicated because many health technology assessment (HTA) methodologies are currently not geared up to evaluate these treatments. ... Yet NICE and many other HTA bodies limit their assessment to the cost-effectiveness of

  • It started with a miss It started with a miss

    Similarly, commercial teams need to drill down and understand HTA requirements within the disease category to ensure trials are designed to capture the necessary data for modelling. ... When drugs don’t receive HTA regulatory support in major markets,

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    That disconnect is evident in drug reviews published by health technology assessment (HTA) bodies, such as the United Kingdom’s National Institute for Health and Care Excellence (NICE). ... HTA bodies are grappling with some of these limitations

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest from PMHub

  • Market Shaping for Better Healthcare Decisions

    In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.

  • Real-world evidence: breaking boundaries in rare disease

    patients. When it comes to rare disease, you need real-world evidence.”. However, we are just starting to understand the power of RWE and many stakeholders, including payers, HTA bodies and

  • Plugging knowledge gaps to demonstrate the benefits of new medicines

    The use of consensus techniques was determined by searching appraisal documents and web sites of UK-based HTA bodies. ... The use of consensus techniques was reported in nine technology appraisals from the three different UK HTA bodies, with numbers

  • Value of Medicines

    David Coleiro, Paula Lashley and John Grime take a look at how society values medicines, the role of health technology assessment (HTA) bodies like NICE, what value means when it comes

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....